These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

389 related articles for article (PubMed ID: 32273721)

  • 1. MET Oncogene in Non-Small Cell Lung Cancer: Mechanism of MET Dysregulation and Agents Targeting the HGF/c-Met Axis.
    Liang H; Wang M
    Onco Targets Ther; 2020; 13():2491-2510. PubMed ID: 32273721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of HGF/MET axis in resistance of lung cancer to contemporary management.
    Raghav KP; Gonzalez-Angulo AM; Blumenschein GR
    Transl Lung Cancer Res; 2012 Sep; 1(3):179-93. PubMed ID: 25806180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Status of Agents Targeting the HGF/c-Met Axis in Lung Cancer.
    Miranda O; Farooqui M; Siegfried JM
    Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30134579
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current mechanism of acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitors and updated therapy strategies in human nonsmall cell lung cancer.
    Zhang K; Yuan Q
    J Cancer Res Ther; 2016 Dec; 12(Supplement):C131-C137. PubMed ID: 28230005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The role of MET receptor tyrosine kinase in non-small cell lung cancer and clinical development of targeted anti-MET agents.
    Robinson KW; Sandler AB
    Oncologist; 2013; 18(2):115-22. PubMed ID: 23345546
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET genetic lesions in non-small-cell lung cancer: pharmacological and clinical implications.
    Zorzetto M; Ferrari S; Saracino L; Inghilleri S; Stella GM
    Transl Lung Cancer Res; 2012 Sep; 1(3):194-207. PubMed ID: 25806181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aberrant
    Al-Ghabkari A; Huang B; Park M
    Cells; 2024 Jan; 13(3):. PubMed ID: 38334610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting the MET gene for the treatment of non-small-cell lung cancer.
    Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M
    Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The c-Met inhibitors: a new class of drugs in the battle against advanced nonsmall-cell lung cancer.
    Sgambato A; Casaluce F; Maione P; Rossi A; Rossi E; Napolitano A; Palazzolo G; Bareschino MA; Schettino C; Sacco PC; Ciardiello F; Gridelli C
    Curr Pharm Des; 2012; 18(37):6155-68. PubMed ID: 22873759
    [TBL] [Abstract][Full Text] [Related]  

  • 10. C-MET inhibitors for advanced non-small cell lung cancer.
    Pasquini G; Giaccone G
    Expert Opin Investig Drugs; 2018 Apr; 27(4):363-375. PubMed ID: 29621416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combining onartuzumab with erlotinib inhibits growth of non-small cell lung cancer with activating EGFR mutations and HGF overexpression.
    Sano Y; Hashimoto E; Nakatani N; Abe M; Satoh Y; Sakata K; Fujii T; Fujimoto-Ouchi K; Sugimoto M; Nagahashi S; Aoki M; Motegi H; Sasaki E; Yatabe Y
    Mol Cancer Ther; 2015 Feb; 14(2):533-41. PubMed ID: 25522765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hepatocyte growth factor/MET in cancer progression and biomarker discovery.
    Matsumoto K; Umitsu M; De Silva DM; Roy A; Bottaro DP
    Cancer Sci; 2017 Mar; 108(3):296-307. PubMed ID: 28064454
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting c-MET in the battle against advanced nonsmall-cell lung cancer.
    Landi L; Minuti G; D'Incecco A; Cappuzzo F
    Curr Opin Oncol; 2013 Mar; 25(2):130-6. PubMed ID: 23385860
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MET Gene Amplification and MET Receptor Activation Are Not Sufficient to Predict Efficacy of Combined MET and EGFR Inhibitors in EGFR TKI-Resistant NSCLC Cells.
    Presutti D; Santini S; Cardinali B; Papoff G; Lalli C; Samperna S; Fustaino V; Giannini G; Ruberti G
    PLoS One; 2015; 10(11):e0143333. PubMed ID: 26580964
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HGF/MET pathway aberrations as diagnostic, prognostic, and predictive biomarkers in human cancers.
    Moosavi F; Giovannetti E; Saso L; Firuzi O
    Crit Rev Clin Lab Sci; 2019 Dec; 56(8):533-566. PubMed ID: 31512514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of HGF-MET Signaling in Primary and Acquired Resistance to Targeted Therapies in Cancer.
    Della Corte CM; Fasano M; Papaccio F; Ciardiello F; Morgillo F
    Biomedicines; 2014 Nov; 2(4):345-358. PubMed ID: 28548075
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MET overexpression and gene amplification in NSCLC: a clinical perspective.
    Landi L; Minuti G; D'Incecco A; Salvini J; Cappuzzo F
    Lung Cancer (Auckl); 2013; 4():15-25. PubMed ID: 28210131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The HGF/c-MET Pathway Is a Driver and Biomarker of VEGFR-inhibitor Resistance and Vascular Remodeling in Non-Small Cell Lung Cancer.
    Cascone T; Xu L; Lin HY; Liu W; Tran HT; Liu Y; Howells K; Haddad V; Hanrahan E; Nilsson MB; Cortez MA; Giri U; Kadara H; Saigal B; Park YY; Peng W; Lee JS; Ryan AJ; Jüergensmeier JM; Herbst RS; Wang J; Langley RR; Wistuba II; Lee JJ; Heymach JV
    Clin Cancer Res; 2017 Sep; 23(18):5489-5501. PubMed ID: 28559461
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidermal Growth Factor Receptor Mutation (EGFR) Testing for Prediction of Response to EGFR-Targeting Tyrosine Kinase Inhibitor (TKI) Drugs in Patients with Advanced Non-Small-Cell Lung Cancer: An Evidence-Based Analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2010; 10(24):1-48. PubMed ID: 23074402
    [TBL] [Abstract][Full Text] [Related]  

  • 20. c-Met expression in renal cell carcinoma with bone metastases.
    Silva Paiva R; Gomes I; Casimiro S; Fernandes I; Costa L
    J Bone Oncol; 2020 Dec; 25():100315. PubMed ID: 33024658
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.